Capricor Therapeutics Inc  

(Public, NASDAQ:CAPR)   Watch this stock  
Find more results for Deborah G Smith
+0.18 (4.18%)
Oct 8 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.22 - 4.50
52 week 3.05 - 10.68
Open 4.22
Vol / Avg. 3,292.00/22,780.00
Mkt cap 69.90M
P/E     -
Div/yield     -
EPS -0.72
Shares 16.25M
Beta -1.86
Inst. own 4%
Nov 10, 2015
Q3 2015 Capricor Therapeutics Inc Earnings Release (Estimated) Add to calendar
Sep 9, 2015
Capricor Therapeutics Inc at Rodman & Renshaw Global Investment Conference
Aug 13, 2015
Q2 2015 Capricor Therapeutics Inc Earnings Call
Aug 13, 2015
Q2 2015 Capricor Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -241.83% -129.87%
Operating margin -237.06% -125.72%
EBITD margin - -124.85%
Return on average assets -48.97% -64.86%
Return on average equity -210.89% -
Employees 28 -
CDP Score - -


United States - Map
+1-310-3583200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Capricor Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company develops and commercializes regenerative medicine and large molecule products for the treatment of disease, with a primary focus on cardiovascular diseases. The Company has six drug candidates in stages of development, which include CAP-1002, CAP-1001, CSps, Exosomes, Cenderitide (CD-NP) and CU-NP. The Company's technology is based in cardiospheres (CSps), which are multi-cell clusters of cardiac derived cells. The Company's product candidate, the cardiosphere-derived cells (CDC), is the single cell monolayer product of the CSps. Both CSps and CDCs are derived from a deceased human donor (allogeneic source) or from heart tissue taken directly from recipient patients themselves (autologous source).

Officers and directors

Frank I. Litvack M.D. Independent Executive Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Linda Marban Ph.D. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Anthony Bergmann Principal Financial Officer and Vice President of Finance
Age: 29
Bio & Compensation  - Reuters
Karen G. Krasney J.D. Executive Vice President, General Counsel
Age: 62
Bio & Compensation  - Reuters
Thomas Lyle Copmann Ph.D. Vice President - Regulatory Affairs and Drug Development
Age: 61
Bio & Compensation  - Reuters
Houman Hemmati M.D., Ph.D. Vice President - Medical & Clinical Development, New Therapies
Bio & Compensation  - Reuters
Luis Rodriguez-Borlado Ph.D. Vice President - Regenerative Therapies
Bio & Compensation  - Reuters
Rachel Smith Ph.D. Vice President - Research & Development
Age: 36
Bio & Compensation  - Reuters
Deborah Ascheim M.D. Chief Medical Officer
Bio & Compensation  - Reuters
Joshua A. Kazam Director
Age: 38
Bio & Compensation  - Reuters